Q-omics provides the consensus-scored C9orf85 profile across patient tissues and cancer cell-line models. C9orf85 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C9orf85 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, C9orf85 RNA expression shows 20,295 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where C9orf85 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C9orf85 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C9orf85 survival associations across molecular data types. C9orf85 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C9orf85 RNA expression–survival associations across cancer types. High C9orf85 expression shows unfavorable associations in ACC, KIRP and LIHC, but favorable associations in KIRC, LGG and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C9orf85 RNA expression.
This table summarizes C9orf85 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for C9orf85. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C9orf85 shows lower tumor expression in THCA, BRCA and KICH and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher C9orf85 RNA expression in tumor versus normal tissue (log2 FC = +0.494, t-test p < 0.001).
This table shows molecular features associated with C9orf85 in patient tissues and cancer cell lines. In patient samples, C9orf85 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C9orf85 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
